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Abstract. Ras family genes (H-, K- and N-ras) are implicated 
in a wide range of human tumours. Mutations are a major 
activating mechanism for the ras family genes, mainly in 
codons 12, 13 and 61, resulting in their conversion from 
proto-oncogenes to activated oncogenes. The detection of 
mutant ras alleles in human tumours has been performed by 
several investigators in a wide range of tissues. The aim of 
our review was to summarize the data obtained from these 
studies and to investigate whether the presence of mutant ras 
alleles was associated with particular clinical parameters. 
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1. Introduction 
Advances in molecular oncology have revealed various roles 
the oncogenes and tumour suppressor genes (TSGs) play in the 
development of cancer (1). These genes usually encode for 
proteins involved in the control of normal cell growth and 
differentiation. Alterations in oncogenes and TSGs affecting 
their expression and function have been recognised as aetio-
logical factors of the disease and are frequently attributed the 
role of molecular markers in tumour progression. 
Among oncogenes, the members of the ras family (H-ras, 
K-ras and N-ras) are the most frequently implicated genes in 
the development of cancer. Ras family genes encode for 
similar proteins with molecular weight of 21,000 Daltons 
(p21). p21 is localised in the inner surface of the plasma 
membrane due to a farnesyl molecule attached to the carboxy 
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terminus of the protein (2). The role of p21 is to transduce 
molecular signals to the cell nucleus, resulting in the activation 
of other cellular genes. The first clue for the role of p21 came 
from the observation that it possesses GTPase activity revealing 
similarities with the G proteins and thus, activating the adenyl 
cyclase pathway (3). Although little is known about the 
expressional patterns and the exact role of the ras family 
genes in human tissues, it is established that p21 is produced 
constitutively in all human tissues, revealing an important 
role of ras genes in normal cell growth (4-6). 
Activation of ras genes in human tumours occurs by 
mutations and aberrant expression. Hot-spots for mutations 
are the codons 12, 13 and 61 (Fig. 1) which participate in the 
GTP binding domain of the protein. The mutant p21 loses its 
ability to become inactivated and thus stimulates cell growth or 
differentiation constitutively. It is suggested that mutations at 
codons 12, 13 and 61 confer a proliferative advantage in the 
cell bearing these mutations and thus they are selected within 
the cell population as compared to other mutations in different 
sites of the ras genes (7). 
The aim of the present report was to review the information 
as regards the incidence of mutations in the ras family genes 
in human tumours. 
2. Methods of detection 
Initially, the most common assay for the detection of mutant 
ras alleles was based on the ability of these alleles to transform 
the mouse NIH/3T3 cell line (8-10). However, although this 
procedure provided an accurate measure of the transforming 
potential of the altered ras genes, it was not suitable for 
examining a large set of tumours because it was time-
consuming and extremely laborious. Recent advances in the 
molecular techniques especially the polymerase chain 
reaction (PCR) and later the characterisation of the hot-spots 
of the mutations, made it possible to examine directly the 
tumour DNA for mutations in specific sites of the ras genes. 
This can be performed by hybridisation of the tumour DNA 
with specific probes for each mutation or alternatively by 
RNase A mismatch cleavage (11,12). The demand for even 
more rapid techniques for the detection of mutant ras genes 
led to the development of PCR based assays which 
distinguish the mutant ras alleles due to a restriction 
fragment length poymorphism (RFLP). These assays are 
based on the ability of specific restriction endonucleases to 
recognise sequences in the ras genes that overlap with the 
codons that behave as hot-spots for the mutations (13). In 
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Figure 1. Structure of the H-ras, K-ras and N-ras genes and localisation of 
the hot spots for mutations. Solid boxes and open boxes indicate coding and 
non-coding exons respectively. 
case that these recognition sites do not naturally occur within 
the ras sequence, they can be entered in the PCR product 
after the use of a mismatch primer (14). All the forementioned 
techniques can be followed by sequencing for the precise 
characterisation of the mutation. 
3. Mutations of ras genes by site 
The frequency of ras mutations varies in the different sites of 
human tumours. A summary indicating the frequencies of ras 
mutations found in tumours located in various sites is shown 
in Table I. 
Pancreas. Tumours of the pancreas are highly malignant and 
characterised by poor prognosis. These tumours, although they 
are not very frequent, harbour mutations in the ras family genes 
at the highest frequency as compared with all other human 
tumours. It has been reported that 90% of the pancreatic 
adenocarcinomas harbour a K-ras mutation (15,16). It is of 
specific interest that all mutations have been detected in K-ras 
and the majority affecting codon 12. This finding indicates a 
specificity in K-ras proto-oncogene in the development of 
pancreatic cancer. Despite the high incidence of mutations in 
carcinomas, the rate of K-ras mutations in ductal papillary 
hyperplasia or intraductal papillary neoplasm (17) was very 
low. 
The strong association of K-ras codon 12 point mutations 
with the development of pancreatic cancer, led several 
investigators to explore a possible clinical significance of this 
finding for diagnosis of the disease. Tada et al (18) detected 
K-ras codon 12 point mutations in the pancreatic juice of all 
cases tested and the peripheral blood in 2 of 6 cases with 
pancreatic adenocarcinoma from circulating metastasising 
cells. In addition, Kondo et al (19) detected mutations at 
codon 12 of K-ras in the pancreatic juice of patients with 
pancreatic cancer, all negative by cytodiagnosis, and proposed 
that the detection of K-ras codon 12 point mutations may be 
a valuable diagnostic modality for pancreatic carcinoma. 
Colon and rectum. Colorectal cancer represents one of the 
best studied and characterised human malignancies at the 
molecular level, mostly due to the availability of the tumour 
Tumour 
site 
ras 
gene 
Frequency 
range (%) 
Pancreas 
Colon and rectum 
Small intestine 
Lung 
Prostate 
Liver 
Skin 
Ovary 
Cervix 
Endometrium 
Stomach 
Bladder 
Breast 
Kidney 
Brain 
Thyroid 
Testis 
Leukaemia 
Head and neck 
K-ras 
K-ras 
H-ras 
K-ras 
H-ras 
K-ras 
K-rai 
N-rai 
H-rai 
K-rai 
N-rai 
K-rai 
K-rai 
K-rai 
H-ras 
H-ras 
K-ras 
K-ras 
N-ras 
K-ras 
H-ras 
K-rai 
N-rai 
K-rai 
N-rai 
N-rai 
K-rai 
H-rai 
K-rai 
80-90 
30-60 
31 
27-60 
0-25 
12-26 
0-46 
0-48 
20 
10-40 
0-41 
7-66 
0-12 
0-50 
0-13 
0-60 
12-43 
6-40 
0-30 
Reference 
No. 
15-16 
21-27 
34 
35-37 
42-46 
47-51 
53-61 
69-71 
72 
62-66 
74-77 
77-79 
80-82 
83-84 
85-88 
89-92 
93-95 
96-106 
107-110 
material for research purposes. Several genetic events have 
been described to play a role in colorectal tumorigenesis, 
including activating mutations in K-rai proto-oncogene. 
Briefly, a mutation in FAP gene, which is located in 5q, leads 
to the generation of a hyperproliferative epithelium. DNA 
hypomethylation and activating mutation in K-rai resulted in 
an adenoma, and the accumulation of deletions to DCC (18q) 
and p53 (17p) in a carcinoma and metastasis (20). 
The role of K-rai gene in colorectal tumorigenesis, became 
apparent after the detection of K-ras mutations in approx. 
40% of colorectal tumours (21-26). Several studies suggest 
association between mutations in K-ras codon 12 and the 
clinical parameters of the patients. Halter et al (23) found 
higher incidence of mutations in patients in stage D, patients 
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with a family history of colon cancer, male patients and long-
term survival in stage D. Yamagata et al (24) found lower 
incidence of K-ras mutations in flat adenomas than in polypoid 
adenomas, suggesting that the adenoma-carcinoma sequence 
through flat adenomas may be different from that through 
polypoid adenomas. Boughdady et al (25) reported that higher 
incidence of mutations in adenomas associates with the size 
of the tumour and the severity of the dysplastic changes. 
Breivik et al (26) performed an exhaustive analysis in 251 
primary tumours in order to assess the incidence of K-ras 
mutations in colon cancer. They found that 39% of the 
specimens harboured a mutation at K-ras gene. Association 
was found with sex, age and tumour location. For colonic 
tumours, young males have fewer mutations than young 
females while rectal tumors show an inverse but less 
pronounced relationship. Spandidos et al (27) investigated 
the incidence of K-ras and N-ras mutations in patients with 
colorectal cancer. They found that 38% of the patients 
harboured a K-ras mutation while the incidence of mutations 
in N-ras gene was limited to 1.5%. Furthermore, point 
mutations appear to be more frequent in carcinomas with 
elements indicating a development from adenoma, in ages 
below 50 years, in females who had the tumour located at the 
rest of the large bowel in comparison with rectosigmoid and 
in higher grade of differentiation. 
The incidence of K-ras mutations in flat adenomas and 
adenocarcinomas was investigated by Minamoto et al (28) who 
found relatively low incidence of K-ras mutations (16% and 
17% respectively), providing further evidence to the hypothesis 
that this type of tumour is a distinct neoplastic entity. 
The data provided on the role of K-ras mutations in the 
development of colorectal cancer, initiated an effort to detect 
K-ras mutations in syndromes predisposing to colorectal 
cancer. Ulcerative colitis (UC) and Crohn's disease are benign 
neoplasms that expose patients to an increased risk for the 
development of colorectal cancer. Although K-ras mutations 
have been detected in approximately 25% of the cases (29), the 
lower rate in addition to the different site distribution (mutations 
are more frequent in rectal carcinomas in comparison to colonic 
carcinomas while the opposite was observed in UC patients) 
as compared to sporadic colorectal tumours (30,31), suggests 
that specific genetic differences may underlie the causation 
of carcinomas arising in these situations. 
Pretlow et al (32) investigated the mutational activation of 
the K-ras gene in the aberrant crypt foci of human colon. 
Since 73% (11/15) of these samples harboured a K-ras 
mutation but none was detected in the 27 morphologically 
normal crypt areas from the same patients they suggested that 
aberrant crypt foci are the earliest precursors of colon cancer 
and mutations at the K-ras gene are the earliest gene 
mutational event in colon tumorigenesis. 
A low incidence of K-ras mutations has also been reported 
in colonic adenomas from familial polyposis coli patients, a 
disease which predisposes patients to the development of 
colorectal cancer, providing evidence that there are common 
molecular events involved in sporadic and hereditary colorectal 
tumorigenesis (33). 
Small intestine. Although the majority of the studies involves 
colorectal tumours little is known as regards the implication 
of the ras family genes in small intestinal tumours. Spandidos 
et al (34) investigated the incidence of point mutations in the 
Η-ras and K-ras genes and found that 4 out of 13 (31%) 
specimens had a Η-ras codon 12 point mutation, while no 
specimens were found positive for a K-ras point mutation. 
These results indicate an association of Η-ras point mutations 
with the development of at least a subset of small intestinal 
tumours. 
Lung. Lung cancer is the leading cause of cancer death in the 
industrialised world, with a high correlation to the smoking 
habits of the patients. As regards the implication of the ras 
family genes several investigators have described activating 
mutations, affecting mainly the K-ras proto-oncogene. Most 
of the mutations have been detected in adenocarcinomas and 
it has been proposed that activating mutations at the K-ras 
proto-oncogene may serve as molecular markers of the disease. 
Rodenhuis and Slebos (35) reported that approximately 
30% of the adenocarcinomas of the lung harbour an activating 
K-ras codon 12 point mutation with almost all the mutations 
in the group of the smokers. In addition they found that 
patients with a K-ras point mutation had significantly worse 
survival than those without an activating mutation at the 
codon 12. Similar results have been reported by a Japanese 
group (36) who found that adenocarcinomas of the lung 
harbour activating mutations at the K-ras gene in approx. 
20% of the specimens. The incidence of Η-ras and N-ras 
point mutations, according to the forementioned study, is 
limited to 1.5% and 4.5% respectively. The same group (36) 
investigated the incidence of ras mutations in squamous cell 
carcinomas, large cell carcinomas, small cell carcinomas and 
adenosquamous cell carcinomas of the lung but mutations were 
found only in squamous cell carcinomas (5.5%) and in large 
cell carcinomas (14%). The highest incidence of K-ras 
mutations in adenocarcinomas of the lung has been reported 
by Husgafvel et al (37) who detected K-ras mutations in 60% 
of the samples tested. Furthermore, they found a strong 
association between the presence of mutation and a heavy 
life-time exposure to tobacco smoke. Apart from smoking, 
exposure to asbestos have also been described to play a rolè 
in the development of K-ras mutations (38,39), providing 
further evidence to the suggestion that ras genes may serve 
as targets of mutagens. Although the majority of the K-ras 
mutations were observed in adenocarcinomas, Rössel et al (40) 
detected higher incidence of K-ras mutations in squamous 
cell carcinomas (21%) than in adenocarcinomas (14%). As 
regards the clinicopathological parameters of the patients, a 
strong association has been found between the presence of 
mutations and the poor survival of patients. Although the 
aetiology of the different K-ras mutation rates, between 
adenocarcinomas and squamous cell carcinomas, is 
unknown, it was postulated that geographical variation may 
play an important role in the K-ras mutational activation. 
In order to examine if K-ras mutations were detectable in 
cytological material from patients with lung cancer, Kiaris et al 
(41) assessed the incidence of K-ras mutations in specimens 
from fine needle aspiration and bronchoscopy. They found 
that approximately 23% of the specimens contained a mutant 
K-ras allele indicating that the detection of K-ras mutations 
may serve as a molecular marker for the detection of the disease. 
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Summarizing, K-ras mutational activation represent a 
frequent event in lung carcinogenesis. The majority of the 
studies described that K-ras mutations occur more frequently 
in adenocarcinomas, however detection of relatively high rates 
of K-ras mutations in other histological entities of lung tumours 
(such as squamous cell carcinomas) remains as a possibility 
which has to be clarified with future investigations. Further­
more, the detection of K-ras mutations was associated with 
poor prognostic indicators, most strikingly with poor survival. 
Apart from the detection of ras mutations in the tumour tissue, 
the detection of activated members of the ras family is possible 
in cytological material of the patients, indicating that the 
detection of mutant raj alleles may serve as a molecular marker 
for the development of the disease. 
Prostate. Prostate cancer is a major cause of death from cancer 
in males in the Western world. However, the implication of 
the raj family genes in the development of prostatic cancer 
has not been studied in depth. Generally, a minor role for the 
ras family genes has been proposed in prostatic cancer. Most 
of the studies demonstrated a low incidence of ras mutations 
(4-10%) and almost exclusively restricted to the Η-ras proto­
oncogene, while mutations at the K-ras and N-ras gene have 
rarely been detected (42-44). However, reports from Greece 
(45) and from Japan (46) demonstrated a relatively high 
incidence (approximately 25%) of ras mutations in prostatic 
cancer, affecting mainly the K-ras proto-oncogene. These 
reports indicate the presence of particular environmental 
factors that may result in the activation of the K-ras gene. 
Although the implication of the ras family genes in the 
development of prostatic cancer is not clearly understood as 
yet, a role of the ras genes in the development of the disease 
should be considered, particularly in association with certain 
environmental factors. 
Liver. Hepatic cancer is characterised by poor prognosis and 
is associated with specific carcinogens such as aflatoxins. 
Mutations in the ras family genes are not very frequent in 
hepatic cancer but when present they are associated with 
specific histopathology of the tumour. 
Tada et al (47) investigated the incidence of ras mutations 
in primary hepatic malignant tumours and found that 26% of 
the tumours tested exhibited evidence of a mutant ras allele. 
All mutations were found in the K-ras gene. Furthermore, 
66% of the cholangiocarcinomas harboured K-ras mutations 
while no mutations were found in hepatocellular carcinomas 
and hepatoblastomas. These results suggest that ras gene 
mutations (K-ras in particular) play an important role in the 
pathogenesis of cholangiocarcinoma. The same group also 
examined a larger set of cholangiocarcinomas and confirmed 
their previous results (48). In this report they found that K-ras 
mutations appear more frequently in the hilar type of intra­
hepatic cholangiocarcinomas and suggested the presence of 
similar etiologic factors in hepatic and colon carcinomas 
since the incidence and spectrum of ras mutations were the 
same in both types of the disease. In addition, K-ras point 
mutations in angiosarcomas of the liver were considered as a 
consequence of vinyl-chloride DNA adduct formation (49). 
In contrast to these results, Challen et al (50) reported a low 
incidence of ras mutations in a subset of hepatocellular 
carcinomas tested. However, 3 among 4 mutations that were 
detected in the 19 patients, were found to affect the N-ras 
gene. This is noteworthly because the incidence of N-ras 
mutations in human solid tumours is rare in the Western 
world. A relatively high incidence of K-ras point mutations 
was reported by Nikolaidou et al (5/41, 12%) in patients from 
Greece (51). 
In conclusion, activation of the ras family genes is 
associated with a particular subtype of hepatic cancers, 
cholangiocarcinomas. 
Skin. Η-ras proto-oncogene is the most frequently activated 
member of the ras family in non-melanoma human skin cancer, 
which is consistent with a model proposed for the mouse skin 
tumorigenesis (52). In most cases, the mutations occur at the 
pyrimidine-rich sequences of the ras genes, indicating that 
these sites are the targets of the DNA induced damage (53). 
However, the high incidence of ras mutations in non-melanoma 
skin cancer has been questioned by Campbell et al (54) who 
failed to detect any mutations in 40 basal cell carcinomas, 12 
squamous cell carcinomas and 12 cases of Bowen's disease. 
Melanomas represent a subset of the skin tumours which 
are characterised by high metastatic potential. Initial studies 
suggested that approximately 20% of the cases presented ras 
mutations the majority of which was found in the N-ras gene 
(55,56). However, these results were not confirmed by other 
investigators who found very low incidence of N-ras mutations 
both in uveal and cutaneus melanomas (57-59). Mutations 
have also been described frequently to activate K-ras gene 
in melanomas (60) but other studies failed to confirm these 
results (58,61). 
Female reproductive tract. Mutations in the ras family genes 
have been detected by several investigators in endometrial 
carcinoma in variable frequence. These mutations affected 
mainly the K-ras proto-oncogene at a rate of approximately 
10-40% (62,63) of the specimens. Furthermore, Enomoto et al 
(63) in order to further define the role of the ras family genes 
in the development of endometrial carcinoma investigated a set 
of premalignant cases of the uterine endometrium. Although 
they failed to find a clear association between the presence of 
a mutation and the development of the disease, their results 
suggested that frequently the presence of a mutation is 
associated with a more aggressive histological type. The 
incidence of K-ras point mutations in premalignant cases of 
endometrium was studied also by Duggan et al (64) who 
suggested that it is an early event in the development of the 
disease. Furthermore, Mizuuchi et al (65) suggested that K-ras 
activation represents an independent risk factor which is 
important in determining the aggressiveness of the disease. 
Association between the presence of the K-ras point mutations 
and the country of origin of the samples has been proposed 
by Sasaki et al (66) who reported that this particular genetic 
aberration occurs more frequently in patients from Japan. In 
addition, the same group suggested that the presence of K-ras 
mutations is associated with a good prognosis. 
Although K-ras point mutations are a relatively uncommon 
event in ovarian carcinomas (67), in different subtypes of 
ovarian neoplasm ras mutations appear to be a more frequent 
feature. In borderline tumours K-ras point mutations were 
INTERNATIONAL JOURNAL OF ONCOLOGY 7: 413-421, 1995 417 
detected in 48% of the specimens (68). Enomoto et al (69) 
detected K-ras mutations in 27% of the specimens and found 
that they occur more frequently in mucinous adenocarcinomas 
than in other epithelial tumours. These results were confirmed 
by a different group (70) who also suggested an association 
between the codon 12 point mutation in mucinous adenomas 
with the occurrence of intestinal type adenomas. Teneriello 
et al (TI) detected K-ras mutations in 30% of low malignant 
potential tumours. It could be argued that K-ras mutations 
are associated with particular subtypes of ovarian neoplasms 
such as borderline tumours, mucinous adenomas and adeno­
carcinomas and low malignant potential tumours. 
In cervical cancer the incidence of ras mutations is relatively 
low as compared to this of the endometrium. Koffa et al (72) 
found that approx. 20% of the cervical tumours harbour an 
activating K-ras mutation of which 28% is found in malignant 
tumours and 5.4% in benign. 
Stomach. The molecular alterations that follow the 
development of gastric cancer are not clearly understood as 
yet. The implication of the ras family genes has been 
investigated by several groups and the majority of the studies 
suggested that ras genes play a minor role in gastric cancer. 
Victor et al (73) found no evidence of H-, K- and N-ras point 
mutations in an analysis involving patients from South 
Africa, where high incidence of gastric cancer was described. 
These results were confirmed by other studies involving 
patients from the Western world (74) and Japan (75) who 
recognised low incidence of activated ras family genes in 
patients with gastric cancer. Although the majority of the 
studies suggest that the members of ras family of genes are 
rarely activated in gastric tumours, Deng et al (76) reported 
that 11 out of 27 (41%) of the cases tested exhibited evidence 
of Η-ras mutations. Furthermore, in the forementioned study 
the presence of Η-ras mutations was associated with distal 
metastases and the survival time of gastric cancer patients 
after surgical operations. 
As regards gastric cancer in general, it is of specific interest 
that the majority of the mutations have been detected in H-ras 
proto-oncogene while colorectal tumours exhibit mutations 
in the K-ras gene (22-27). We may postulate that this is due 
to the different carcinogens present in each tissue. 
Bladder. Bladder tumours harbour activating mutations in the 
ras family genes in approximately 7-17% of the samples 
(77,78). Contrary to the majority of the tumours that harbour 
an activated K-ras allele, the Η-ras proto-oncogene is activated 
in bladder tumours, providing evidence for the tissue specificity 
of the ras family genes. High incidence of ras mutations in 
bladder tumours has been reported by Haliassos et al (79) 
who detected Η-ras codon 12 point mutations in 66% of the 
specimens with a combined PCR-RFLP assay. The same group 
detected the mutant Η-ras allele in the urine of 47% of the 
patients with bladder tumour suggesting that the detection of 
this aberration may have a prognostic value for the detection 
of the neoplasia (79). 
Breast. Breast cancer represents a major cause of death in 
adult females. Several alterations at the molecular level have 
been associated with the development of the disease, such as 
overexpression of the c-erbB-2 and mutations and aberrant 
expression of the p53 tumour suppressor gene. In addition, in 
hereditary breast cancer recent studies revealed three altered 
loci with deletions and/or mutations, that led to the 
development of cancer. 
The implication of ras genes in breast cancer have been 
studied mainly at the level of overexpression. Mutations in the 
ras family is generally considered as a rare event in the 
development of the disease (80,81). Koffa et al (82) found 
that 8 among 65 (12%) harbour an activating K-ras mutation. 
All the mutations were restricted to high grade tumours (II and 
III) indicating that this particular aberration is a late event in 
the development of the disease. 
Kidney. The implication of the ras genes in the development 
of cancer of the kidney has not been studied in depth as yet. 
However the available data indicate that ras mutations are 
rare events in the development of this cancer (83) However, a 
special category of cancer of the kidney, occurring in patients 
after kidney transplantations, may exhibit higher incidence of 
ras mutations. This has been proposed by Skalkeas et al (84) 
who suggested that K-ras codon 12 point mutations is a 
common event in kidney transplanted patients who develop 
neoplasia, even in the least aggressive forms of the disease, 
contrary to the sporadic cases. 
Brain. The absence of ras mutations in glioblastomas and 
neuroblastomas has been reported by two groups (85,86) 
while a role for the ras genes in the development of brain 
tumours has been proposed by Brustle et al (87) who detected 
an activated K-ras gene in one among 9 neuroectodermal 
tumours tested. In addition, Ireland (88) reported 2 specimens 
positive for N-ras mutations among 15 (13%) in neuro­
blastomas. However, future studies involving larger set of 
specimens should be performed in order to define the role of 
the ras genes in the development of brain tumours. 
Thyroid. Mutations in all three ras family genes have been 
found in thyroid tumours. The highest incidence of mutations 
was found in follicular and undifferentiated carcinomas (89,90) 
while in papillary carcinomas the incidence of ras mutations 
was limited (89,91,92). Macrofollicular hyperplasias are 
characterised by the absence of mutations in the members of 
the ras family (90). 
Testis. A significant incidence of ras mutations has been 
reported in testicular tumours, mainly in seminomas. The 
majority of the mutations were detected in K-ras and N-ras 
proto-oncogenes (93). However the high incidence of ras 
mutations in testicular cancer was not confirmed by other 
investigators (94,95), probably due to the small number of 
specimens included in these studies. Investigation of a larger set 
of tumours should be performed in order to establish the precise 
role of mutant ras alleles in the development of testicular 
cancer. 
Leukaemia. An activated member of the ras family has been 
detected in approximately 30% of the patients with acute 
myeloid leukaemia (96-99). The point mutations occur in the 
N-ras (mainly) and K-ras while in the Η-ras gene point 
mutations have rarely been detected. As regards the clinical 
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aspects of the patients harbouring mutant ras alleles it appears 
that the cell clones with ras mutations exhibit more resistance 
to chemotherapy as compared to the cell clones with normal 
ras genes (100). However, no particular association has been 
found between the ras mutation and the pathological features 
of the patients. Mutations in the ras family genes have also 
been detected in patients with myelodysplastic syndromes 
(101), at significant frequency. However, the presence of the 
mutation was not associated with the development of acute 
leukemia (AL), indicating that this particular aberration in 
the ras genes could not serve as a prognostic factor (101,102). 
Vashiukin et al (103) detected activated N-ras alleles in the 
blood plasma of patients with AL or myelodysplasia syndrome 
(MDS) and proposed that plasma could be a useful material 
for monitoring myeloid disorders. 
The incidence of ras mutations in lymphoid malignancies 
is not as high as that reported in myeloid disorders (104,105). 
It might be postulated that the tumorigenic potential conferred 
by the mutant ras alleles in lymphocytes is lower than this in 
myeloid cells. However, although Lubbert et al (106) detected 
N-ras mutations in only 6% of the patients they found a strong 
association between the presence of N-ras mutations and poor 
prognosis. 
Head and neck. Activated members of the ras family are rarely 
detected in head and neck tumours and the average incidence 
of ras mutations is approx. 5% only (107-109). However, 
Saranath et al (110) detected ras mutations in 35% of the 
specimens and found that mutations were associated with the 
chewing of tobacco. This finding provides further evidence to 
the suggestion that ras genes frequently behave in a carcinogen 
specific manner. 
4. Alternative methods of activation for the ras family genes 
Apart from point mutations, a polymorphism of the ras alleles 
(at least H-ras) may be associated with the development of 
the malignancy (111) corresponding to the number of the 
repetition of a core 28 bp repeat, at the 3' end of the gene 
(VTR). Four main VTR alleles have been recognised and 
several rare alleles with intermediate length. The presence of 
rare VTR alleles has been proposed to associate with increased 
probability for the development of cancer. In addition, Kiaris 
et al (109) suggested that instability of this region may be 
associated with the deregulation of the H-ras gene. Furthermore, 
loss of heterozygosity of the H-ras locus (112), amplification 
of K-ras and N-ras genes (113) and abnormal methylation 
(114) of the ras family genes have also been described in 
human tumours and may be associated with the development 
of the disease. 
Structural alterations represent the major, but not the only 
activating mechanism for the ras family genes in human 
tumours. Overexpression of p21 r a s is frequently recognised in 
several human cancers. The majority of the studies have 
involved the immunohistochemical detection of p21 (115-117) 
but a subset of the studies also recognised elevated levels of 
ras mRNA in human tumours (109,113,118,119). The 
overexpression of ras family genes does not necessarily 
requires the existence of point mutated ras alleles because 
the normal ras alleles have been proved to confer a tumorigenic 
potential when overexpressed (120). 
Codon 12 Codon 13 
5*-GGT GGC....-3' 
Pancreas 
Colon 
Lung 
A Τ C A Τ C 
Figure 2. Typing of the commonest K-ras codon 12 point mutations 
detected in pancreatic, colorectal and lung tumours. Data were obtained 
from literature cited in the text. 
5. Conclusions and perspectives 
The forementioned data summarise the present state of 
information as regards the implication of the ras family 
genes in the development of human tumours in vivo. The 
analysis concentrated on the detection of activating point 
mutations and excluded alternative methods of activation. It 
is obvious that ras family genes are involved in a wide range 
of human tumours and in particular cases (such as pancreatic, 
lung and colon cancer) at a significant rate (Table I, Fig. 2). 
Furthermore, the detection of activating point mutations is 
frequently associated with an aggressive type of the disease 
and with specific clinical characteristics (Table II). 
The clarification of the role of activated ras alleles in 
human tumours, may have significant implication in the 
clinical practice. The presence of mutant ras alleles may serve 
Table II. Association of ras mutations with prognosis. 
Tumour tissue 
Colon (stage D) 
Lung 
Leukaemia 
Endometrium 
Stomach 
mutant ras 
K-ras 
K-ras 
N-ras 
K-ras 
H-ras 
Prognosis 
favourable 
poor 
poor 
poor 
poor 
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as molecular markers for the development of the disease. 
Biopsy specimens from surgically resected tumours may be 
assayed for the presence of ras mutations and this may help 
to predict the course of the disease or to establish treatment 
strategies (i.e. in leukemias). Furthermore, the detection of ras 
mutations may provide useful information as regards the 
early detection of the disease. In this case cytological material 
might be used (i.e. in lung cancer) in order to screen the 
population for the presence of mutant K-ras alleles (121). 
A m o r e c h a l l e n g i n g p o s s i b i l i t y is the use of the 
forementioned information for the therapy of cancer. Such an 
approach has been successfully carried out in vitro by specific 
compounds (antisense oligonucleotides and inhibitors of 
farnesylation) that block ras genes at the level of transcription 
or post-transcriptional modifications respectively (122,123). 
Studies involving large number of specimens, in association 
with detailed clinical parameters should be performed, in order 
to reveal the precise role of the ras family genes in human 
cancer and to apply this information in clinical practice. 
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